The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches. by Geloso, Mc (ORCID:0000-0002-0622-9813) et al.
MINI REVIEW
published: 25 July 2017
doi: 10.3389/fnagi.2017.00242
The Dual Role of Microglia in ALS:
Mechanisms and Therapeutic
Approaches
Maria Concetta Geloso1*, Valentina Corvino1, Elisa Marchese1, Alessia Serrano1,
Fabrizio Michetti1,2 and Nadia D’Ambrosi3*
1Institute of Anatomy and Cell Biology, Università Cattolica del Sacro Cuore, Rome, Italy, 2IRCCS San Raffaele Scientific
Institute, Università Vita-Salute San Raffaele, Milan, Italy, 3Department of Biology, University of Rome Tor Vergata, Rome, Italy
Edited by:
Yu Tang,
University of Texas Southwestern
Medical Center, United States
Reviewed by:
Yolanda Diz-Chaves,
Institute of Biomedical Research of
Vigo (IBIV), The Biomedical Research
Centre (CINBIO), Spain
Neha Sehgal,
Children’s Hospital of Philadelphia,
United States
James C. Vickers,






Received: 30 March 2017
Accepted: 11 July 2017
Published: 25 July 2017
Citation:
Geloso MC, Corvino V, Marchese E,
Serrano A, Michetti F and
D’Ambrosi N (2017) The Dual Role of
Microglia in ALS: Mechanisms and
Therapeutic Approaches.
Front. Aging Neurosci. 9:242.
doi: 10.3389/fnagi.2017.00242
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by a
non-cell autonomous motor neuron loss. While it is generally believed that the disease
onset takes place inside motor neurons, different cell types mediating neuroinflammatory
processes are considered deeply involved in the progression of the disease. On these
grounds, many treatments have been tested on ALS animals with the aim of inhibiting
or reducing the pro-inflammatory action of microglia and astrocytes and counteract
the progression of the disease. Unfortunately, these anti-inflammatory therapies have
been only modestly successful. The non-univocal role played by microglia during
stress and injuries might explain this failure. Indeed, it is now well recognized that,
during ALS, microglia displays different phenotypes, from surveillant in early stages,
to activated states, M1 and M2, characterized by the expression of respectively harmful
and protective genes in later phases of the disease. Consistently, the inhibition of
microglial function seems to be a valid strategy only if the different stages of microglia
polarization are taken into account, interfering with the reactivity of microglia specifically
targeting only the harmful pathways and/or potentiating the trophic ones. In this review
article, we will analyze the features and timing of microglia activation in the light of
M1/M2 phenotypes in the main mice models of ALS. Moreover, we will also revise
the results obtained by different anti-inflammatory therapies aimed to unbalance the
M1/M2 ratio, shifting it towards a protective outcome.
Keywords: amyotrophic lateral sclerosis, M1/M2 microglia, neuroinflammation, anti-inflammatory drugs, genetic
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ALS AS A COMPOSITE DISEASE
Amyotrophic lateral sclerosis (ALS) is amultifactorial disease caused by genetic and non-inheritable
components leading to motoneuron degeneration in the spinal cord, brain stem and primary motor
cortex (Al-Chalabi and Hardiman, 2013). Most of ALS cases are sporadic (sALS), while 5%–20%
report a familial history of the disease (fALS; Al-Chalabi et al., 2017). sALS and fALS share most
neuropathological features and, from a clinical perspective, they appear very similar (Talbot,
2011). Pathological hallmarks characterizing degenerating motoneurons are cytoplasmic inclusions
containing aggregated/ubiquitinated proteins as well as RNAs. Indeed, protein misfolding,
with endoplasmic reticulum (ER) stress, impaired autophagy and damage to cytoskeleton are
intracellular mechanisms involved in the pathogenesis of the disease (Taylor et al., 2016).
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However, ALS appears as a composite syndrome where the
aberrant cellular pathways may not derive solely from a
conformational issue, but involve many aspects of cellular
physiology: RNA processing and mitochondria homeostasis
are compromised, oxidative stress is increased, excitotoxic
pathways are enhanced, neurotrophic support is reduced,
glial inflammatory response is oriented towards an harmful
side (Rossi et al., 2016). Actually, more than 40 genes have
been found mutated in ALS, affecting numerous cellular
functions (Al-Chalabi et al., 2017), the most relevant of
which are: a hexanucleotide repeat (GGGGCC) expansion
in an intron of the C9orf72 gene (Dejesus-Hernandez et al.,
2011; Renton et al., 2011), supposed to generate toxic RNA
species, loss of protein and/or harmful dipeptide-repeats
formation (Haeusler et al., 2016); superoxide dismutase 1
(SOD1; Rosen et al., 1993), forming toxic aggregates and
interfering with mitochondrial functions and autophagy (Turner
and Talbot, 2008). In this regard, transgenic SOD1 mice
are so far the most widely used model to study ALS. Both
active (SOD1G93A, SOD1G37R) and inactive (SOD1G85R)
mutants show a phenotype characterized by a progressive
paralysis and death (at 5, 7 and 8.5 months, respectively),
caused by degeneration of motoneurons (limited to 40%
in SOD1G85R mice), and exhibit gliosis within the spinal
cord, brain stem and cortex (Philips and Rothstein, 2015),
suggesting that neurodegeneration relies on a gain of toxic
function of the protein. Other mutated proteins are fused
in sarcoma (FUS; Kwiatkowski et al., 2009; Vance et al.,
2009) and TAR-DNA binding protein-43 (TDP-43; Neumann
et al., 2006), involved in the maturation of mRNAs, found
in cytoplasmic inclusions (Guerrero et al., 2016); proteins
regulating cytoskeleton architecture, such as profiling-1
(Wu et al., 2012; Yang et al., 2016), and vesicle trafficking,
as vesicle-associated membrane protein/synaptobrevin-
associated membrane protein B (Nishimura et al., 2004;
Tsuda et al., 2008); autophagy-linked proteins, among which
sequestosome 1 (Teyssou et al., 2013), optineurin (Nakazawa
et al., 2016) and TANK-binding protein kinase-1 (TBK-1;
Cirulli et al., 2015; Freischmidt et al., 2015). Mutations in
these genes also affect the function of cell types other than
motoneurons. Indeed, ALS is non-cell autonomous, as astrocytes
andmicroglia can participate to determine the disease phenotype
by a local inflammatory response (neuroinflammation) and
characterized by phenotypic transition, migration to the site
of injury, proliferation and secretion of pro-inflammatory
mediators (Philips and Rothstein, 2014). Glial activation
leads to changes in the expression of a wide range of genes
related to the production of soluble molecules, such as
cytokines and chemokines, damage–associated molecular
patterns (DAMPs), reactive nitrogen and oxygen species (ROS),
giving rise to profound modifications in their interactions
with neurons (Becher et al., 2017). Actually, a noticeable
level of neuroinflammation has been detected in both sALS
and fALS, as well as in transgenic models of the disease
(Troost et al., 1989; Engelhardt and Appel, 1990; Schiffer
et al., 1996; Hall et al., 1998; Henkel et al., 2004, 2006). Signs
of microglia reactivity have been detected well before overt
symptoms onset (Brites and Vaz, 2014; Tang and Le, 2016),
concomitantly with loss of neuromuscular junctions (Gerber
et al., 2012) and early motoneuron degeneration (Alexianu et al.,
2001).
The role of microglia has been strengthened by recent
studies opening new perspectives in the knowledge of the
non-cell autonomous molecular pathways possibly contributing
to ALS.
Lack of C9orf72 in a loss-of-function model of the
disease produced no signs of motoneuron degeneration,
but led to lysosomal accumulation and altered immune
responses in macrophages and microglia (O’Rourke et al., 2016).
Furthermore, the recently described ALS-susceptibility gene,
TBK1, not only has a central function in autophagy processes,
but is involved in innate immunity signaling pathways, regulating
the production of interferon α (IFN α) and IFN β (Ahmad et al.,
2016). A close relation between disruption of the autophagy
machinery and microglial activation has been recently proposed
(Plaza-Zabala et al., 2017): hence, an impaired autophagy linked
tomodifications in the response to pro-inflammatory stimuli and
pathogen clearance by resident immune cells likely contributes
to the etiopathology of the disease. Recent data show an
earlier and more detrimental clinical course in SOD1G93A mice
lacking telomerase (Linkus et al., 2016), evidencing therefore
a possible aging effect on microglia priming in ALS. Indeed
aged and mutant SOD1 (mSOD1)-expressing microglia display a
common signature of gene expression, as well as specific patterns
(Holtman et al., 2015).
In this review article, we therefore describe how the adaptive
phenotypes of microglia participate to neurodegeneration in
ALS, evidencing how the concept of a bipolar, protective vs.
harmful, response of microglia has been rapidly changed in less
than a decade. We also discuss how anti-inflammatory drugs
have been used to polarize microglia towards a neuroprotective
signature to control the extent of activation and if and how this
has reached therapeutic benefits.
M1/M2 PHENOTYPE IN ALS
Overview
Microglia are largely considered as the brain’s resident immune
cell, which has been classically described to exist in two
states, resting and activated (Cherry et al., 2014). In the
adult healthy brain, two-photon imaging showed that the so
called ‘‘resting’’ microglia is, in actual facts, a highly dynamic
population (Nimmerjahn et al., 2005), which actively screen
their microenvironment with motile processes, exerting a crucial
role in maintaining homeostasis (Luo and Chen, 2012). It
is indicated as ‘‘surveillant’’ microglia and participates to
many physiological functions, including synaptic pruning, adult
neurogenesis and modulation of neuronal networks (Walton
et al., 2006; Kettenmann et al., 2013).
This highly specific interaction with the extracellular
environment is tightly regulated (Nimmerjahn et al., 2005;
Parisi et al., 2016b), therefore these cells rapidly react to
abnormalities, adopting a less ramified/amoeboid phenotype,
corresponding to activated microglia (Luo and Chen, 2012;
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FIGURE 1 | M1/M2 microglia polarization during amyotrophic lateral sclerosis (ALS)-induced motor neuron degeneration. During ALS progression activated microglia
represent a continuum between the neuroprotective M2 phenotype, which promotes tissue repair and supports neuron survival by releasing neuroprotective factors,
vs. the toxic M1, which produces cytokines increasing inflammation and further supporting M1 polarization, thus contributing to neuronal death. Therapeutic
approaches targeting microglia polarization and resulting in induction of the M2 phenotype are promising strategies to ameliorate local neurodegeneration and
improve the clinical outcome of the disease (see Table 1 for details).
Cherry et al., 2014). Similarly to peripheral macrophages, the
term activation has been associated at least with two distinct
phenotypes, M1 (toxic) and M2 (protective), in response to
different microenvironmental signals, in turn involved in the
production of a variety of effector molecules (Du et al.,
2016). Microglia recognize pathogens via pattern recognition
receptors, which interact with classes of DAMPs derived
from exogenous microorganisms or endogenous cell types
involved in immunity processes, respectively. The interaction
triggers a downstream gene induction program aimed at
initiating cellular defense mechanisms, including the release of
inflammatory cytokines and chemokines (Colton, 2009; Kigerl
et al., 2014).
In particular, in in vitro settings, lipopolysaccharide (LPS)
or IFN-γ stimulate ‘‘classically activated’’ M1 microglia,
which release pro-inflammatory mediators. They include
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pro-inflammatory cytokines (interleukin [IL]-1α, IL-1β, IL-6,
IL-12, IL-23, tumor necrosis factor-α [TNF-α]), chemokines,
prostaglandin E2, chemokine (C-C motif) ligand 2, ROS and
inducible nitric oxide synthase (iNOS; Bagasra et al., 1995; Du
et al., 2016; Orihuela et al., 2016).
In contrast, ‘‘alternatively activated’’ M2 phenotype,
which is induced by anti-inflammatory cytokines IL-4,
IL-10 or IL-13, suppresses inflammation, clears cellular
debris through phagocytosis, promotes extracellular matrix
reconstruction and supports neuron survival through the release
of protective/trophic factors (Hu et al., 2015; Du et al., 2016;
Tang and Le, 2016). ‘‘Acquired deactivation’’ represents another
M2 anti-inflammatory phenotype and it is mainly induced by
the uptake of apoptotic cells or exposure to anti-inflammatory
cytokines, such as IL-10 and transforming growth factor-β (Tang
and Le, 2016).
Microglia in ALS
Studies investigating the progression of the disease in ALS
mice indicate that, in vivo, resident microglia increase their
number during disease progression, and their activation states
represent a continuum between the two classical phenotypes,
i.e., neuroprotective M2 vs. toxic M1 (Liao et al., 2012; Chiu
et al., 2013; Figure 1). In line with this, the occurrence of
two different phenotypes of microglial cells, on the basis of
their morphology, has been recently described in SOD1G93A
transgenic mice: type ‘‘R1’’, showing short and poorly branched
processes, which represents the vast majority of microglia
in the early-stage of the disease and corresponding to early
transformation of surveillant microglia, and type ‘‘R3’’ microglia,
exhibiting large cell bodies with short and thick processes,
which are typical of end-stage phases of the disease (Ohgomori
et al., 2016). Consistently, microglia have been shown to
exhibit, at the pre-onset phase of SOD1-mediated disease,
an anti-inflammatory profile with attenuated TLR2 responses
to controlled immune challenge, and a overexpression of
anti-inflammatory IL-10 (Gravel et al., 2016). Subsequently,
at disease onset and during the slowly progressing phase, the
prevalent expression of specific M2 markers, (e.g., Ym1 and
CD206), was detected in the lumbar spinal cords of ALS
mice (Beers et al., 2011a). Eventually, in end-stage animals,
a microglial phenotype expressing high levels of NOX2,
the subunit of nicotinamide-adenine-dinucleotide-phosphate
oxidase expressed by macrophages considered M1 prototypic
marker, appears to be prevalent (Beers et al., 2011b).
M1 ALS microglia appear hyper-reactive to inflammatory
stimuli (D’Ambrosi et al., 2009) and the specific role of mutated
proteins in driving this increased toxicity has been suggested by
many studies (Beers et al., 2006; Xiao et al., 2007; Liao et al.,
2012). Mutant forms of TDP-43 are able to activate microglia and
upregulate the release of pro-inflammatory mediators, including
NOX2, TNF-α and IL-1β (Zhao et al., 2015). Consistently,
also the intracellular expression of high levels of TDP-43
underlies the occurrence of a more toxic microglial phenotype,
when stimulated, in vitro, with LPS or ROS (Swarup et al.,
2011).
Similarly, exogenous SOD1G93A or SOD1G85R induce, in vitro,
morphological and functional activation of microglia, increasing
their release of pro-inflammatory cytokines and ROS (Zhao
et al., 2010). In chimeric mice with both normal and
mSOD1-expressing cells, non-neuronal cells that do not
express mSOD1, including microglia, delay degeneration and
significantly extend survival of mutant protein-expressing
motoneurons (Clement et al., 2003). Interestingly, also mSOD1-
expressing microglia underlie phenotypic transformation during
the disease. More specifically, evidence has been provided
that, when co-culturing different-aged mSOD1 microglia with
WT motoneurons, mSOD1-expressing early-activated microglia
exhibit neuroprotective features, enhancing neuronal survival,
while end-stage derived mSOD1microglia show toxic properties,
increasing neuronal death rate (Liao et al., 2012). Additionally,
mSOD1 microglia shows increased expression of molecular
players of the ER stress pathway (Ito et al., 2009), which may be
involved in their toxic phenotype.
At the molecular level, mutated proteins, including TDP-43
and FUS, induce the selective activation of nuclear factor-kappa B
(NF-kB), master regulator of inflammation (Frakes et al., 2014).
On this basis, the possibility to appropriately modulate
microglial phenotypes, enhancing the anti-inflammatory
properties and inhibiting or reducing M1 toxicity, could
be a promising therapeutic strategy for ALS, therefore a
comprehensive knowledge of both timing and molecular
players of microglial activity is needed. However, emerging
evidence suggests that the M1/M2 paradigm seems to be an
oversimplification (Ransohoff, 2016) and substantial differences
between microglia and peripheral macrophages, from which
the terminology derives, should be carefully considered. As
resident macrophages of the brain, microglia have an elaborate
repertoire of brain specific functions, sustained by a peculiar
gene expression profiling (Gautier et al., 2012). In vitro,
phenotypic redirection is a feature of peripheral macrophages,
while microglia exhibit a lower grade of plasticity (Parisi et al.,
2016b). Coexistence of the two opposite phenotypes, more than
transition fromM2 to M1, during ALS progression has also been
recently highlighted by several findings. For instance, beneficial
components of inflammation, such as insulin growth factor-1
(IGF-1), whose release is suppressed in a pro-inflammatory (M1)
environment but encouraged in an M2 protective environment
(Suh et al., 2013), is overexpressed by SOD1G93A microglia not
only in pre-symptomatic stage, but also in end-stage (Chiu
et al., 2008). Furthermore, a down-regulation of IL-6 over time,
associated with an up-regulation of IL-1R antagonist, has been
reported, suggesting the occurrence of an anti-inflammatory
response (Chiu et al., 2008). Analysis of transcriptome
changes of SOD1G93A microglia essentially confirmed these
observations. They also evidenced that the activation of genes
involved in anti-inflammatory pathways, including, Igf1,
Progranulin and Trem2, coexists with the upregulation of
genes related to potentially neurotoxic factors, among which
Matrix metalloproteinase-12 and classical proinflammatory
cytokines, (Chiu et al., 2013). Interestingly, critical differences
in gene expression profiling among M1/M2 macrophages,
LPS-activated microglia and SOD1G93A activated microglia
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emerge: while LPS-activated microglia show enriched in
DNA replication-, cell cycle- and innate immune signaling-
genes, SOD1G93A activated microglia are enriched in the
transcripts of genes related to neurodegenerative diseases,
e.g., AD, Huntington’s and Parkinson’s disease, suggesting
a neurodegeneration-specific signature for ALS microglia.
More interestingly, SOD1G93A-expressing microglia do not
display a significant prevalence of M1 or M2 phenotypes at
any time point during disease progression (Chiu et al., 2013).
In line with this results, an increased expression of both
iNOS (M1 marker) and arginase 1 (Arg1; M2 marker) has
been shown to parallel the generalized increase of activated
microglia in SOD1G93A mice (Lewis et al., 2014). Consistently,
characteristics different from typical M1 or M2 phenotypes have
been reported in end-stage SOD1G93A rats, which also show
predominant microglial activation in most severely affected
regions (lumbar spinal cord), as if several phenotypically
different microglial subpopulations were present throughout
differently affected regions of the CNS (Nikodemova et al.,
2014).
MICROGLIAL SWITCH AND THERAPEUTIC
APPROACHES IN ALS ANIMAL MODELS
Targeting the microglia has been the focus of neuroprotective
strategies, based on pharmacological or genetic approaches,
aimed at modulating microglia reactivity in the attempt to
improve the clinical outcome in animal models of the disease
(Table 1, Figure 1). In this regard, pioneer studies based on
administration of minocycline, a tetracycline antibiotic that
prevents microglial activation, showed that, when administered
in both SOD1G93A and SOD1G37R mice before disease onset,
it attenuates microglial activation and delays disease onset and
mortality (Kriz et al., 2002; Van Den Bosch et al., 2002; Zhu
et al., 2002). On the other hand, when administered after
the onset of the disease, it fails to improve clinical and/or
pathological features, even increasing microgliosis (Keller et al.,
2011). Interestingly, recent findings obtained in SOD1G37R
mice have shown that minocycline specifically attenuates
the M1 phenotype, without influencing the expression of
M2 markers (Kobayashi et al., 2013; Table 1), thus highlighting
the crucial role exerted by the modulation of M1/M2 balance in
the therapeutic effectiveness.
Hence, pharmacological modulation of molecular pathways
related to microglial polarization has been explored. The
hyperactivation of P2X7 receptors, strongly involved in
neuroinflammatory response (Burnstock, 2008; Apolloni
et al., 2009; Volonté et al., 2012; Sperlágh and Illes, 2014), has
been described in microglia of both ALS patients and animal
models (Yiangou et al., 2006; D’Ambrosi et al., 2009), where
it is associated to the production of pro-inflammatory factors,
including miR-125b (D’Ambrosi et al., 2009; Parisi et al., 2013,
2016a). Consistently, the administration of the P2X7 antagonist
Brilliant Blue G (BBG), within a critical time frame, improves
several features of the disease (Cervetto et al., 2013; Apolloni
et al., 2014). BBG neuroprotection, obtained at late pre-onset
administration, is supported by the upregulation of IL-10 and
BDNF, associated to M2 phenotype, together with a reduction
of NF-kB protein, NOX-2 and IL1β, markers of M1 polarization
(Table 1). However, BBG administration at earlier phases fails to
counteract disease progression. In this case, although it reduces
M1 markers, it does not affect the expression of M2 mediators,
whose neuroprotective properties seem to be essential to improve
the clinical outcome (Apolloni et al., 2014).
Microglia-mediated neuroinflammation is also modulated by
histamine (Ferreira et al., 2012; Volonté et al., 2015; Barata-
Antunes et al., 2017). The antihistamine drug Clemastine,
administered to SOD1G93A mice at the asymptomatic phase until
the end-stage of disease, fails to improve clinical symptoms
and lifespan, although it modulates the M1/M2 balance by
reducing CD68, NOX2 and P2X7 expression and concomitantly
up-regulating Arg1 (Apolloni et al., 2016b; Table 1). Conversely,
when administered at the asymptomatic phase to the onset, it
delays the disease onset and improves the motor functions and
survival rate (Apolloni et al., 2016a). Clemastine also activates
autophagy in SOD1G93A primary microglia, thus suggesting
that targeting autophagy in microglia could be a promising
therapeutic strategy (Apolloni et al., 2016a).
Alternative therapeutic strategies to shift the balance towards
the M2 phenotype involve the use of trophic factors. Several
findings showed that the delivery of viral vectors encoding
growth factors, such as IGF-1, glial-derived neurotrophic factor,
vascular endothelial growth factor (VEGF) extends lifespan and
slows the progression of the disease in ALS animal models
(Acsadi et al., 2002; Kaspar et al., 2003; Azzouz et al., 2004;
Dodge et al., 2010; Wang et al., 2016). Interestingly, the
intrathecal injection of self-complementary adeno-associated-
virus (scAAV)9-VEGF at disease onset decreases TNF-α, IL-1β
and CD68 levels and increases those of Arg-1 and Ym-1
(Table 1), showing that the modulation of M1/M2 balance could
support the protective effects correlated to VEGF administration
(Wang et al., 2016).
Further, the deletion of the cystine/glutamate-antiporter
xCT/Slc7a11 (xCT), a critical glial transporter system involved in
the excessive glutamate release from M1 microglia, has provided
additional finding on this matter. Indeed, xCT deletion at the
early-stages of the disease, in fact, increases the expression
of M1 marker IL1β and concurrently reduces M2 marker
Ym1/Chil3, thus resulting in earlier disease onset. Conversely,
lack of xCT, at the end-stage, increases Ym1/Chil3 and
Arg1 expression, which possibly sustains the delay of disease
progression (Mesci et al., 2015; Table 1).
These data underline that the modulation of microglia-
specific pathways may ameliorate local neurodegeneration.
However, growing evidence suggests that a successful therapeutic
strategy for ALS could be obtained only interfering with different
pathways in different cell types. In light of this, it was recently
demonstrated that microglial NF-κB suppression combined with
mSOD1 reduction in astrocytes and motoneurons results not
only in attenuated neuroinflammation and neurodegeneration,
but also increases mice mean survival (Frakes et al., 2017),
demonstrating that the redirection of microglia polarization may
still be an effective strategy to counteract ALS when associated
with the interception of other pathogenic mechanisms.
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